Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... (68% v 28%, P = .02) but similar for all arms across cytogenetic subgroups, as was remission duration and overall survival. ORR was higher with mutations in ...

    Research Article last updated 05/22/2017 - 10:52am.

  2. Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

    ... Acute myeloid leukemia who fail to achieve complete remission with one course of induction chemotherapy or after relapse. ... M7 classification; (v) treatment-related AML. (vi) residual cytogenetic or molecular abnormalities Myelodysplastic syndromes ...

    Clinical Trial last updated 06/06/2016 - 1:18pm.

  3. Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

    ... Treatment Portion: AML in 1st remission - for patients whose AML does not have "good risk" cytogenetic features (i.e. t (8;21), t(15;17), inv 16 without c-kit mutations). ...

    Clinical Trial last updated 04/29/2016 - 1:11pm.

  4. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the Europ

    ... At time of HSCT, 32% of patients did not achieve complete remission (CR) and 13% had primary refractory disease. On univariate ... 5.26; P = .016). In addition, an adverse effect of IPSS-R cytogenetic risk group was evident for RFS. In summary, outcomes after HSCT are ...

    Research Article last updated 07/18/2016 - 11:22am.

  5. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

    ... or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell ... survival. In patients with intermediate/high risk cytogenetic abnormalities the hazard ratio in multivariate analysis was 0.58 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

    ... cell transplantation is indicated such as: AML in 1st remission - for patients whose AML does not have 'good risk' cytogenetic features (i.e. t 8;21, t15;17, inv 16). Secondary AML in 1st ...

    Clinical Trial last updated 04/29/2016 - 3:18pm.

  7. Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes

    ... bacteremia (P=0.0005). Among patients achieving a complete remission with the initial course cycle, grade 4 neutropenia was associated ... bacteremia. After adjustment for age, gender, disease type, cytogenetic risk, and performance status, the risk of documented infection or ...

    Research Article last updated 01/07/2014 - 12:42pm.

  8. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... and RAEB-t (AML with 21%-30% marrow blasts ) in 22%. Cytogenetic risk was good in 31%, intermediate in 17%, and poor in 47%. ... in patients who did not obtain complete or partial remission was associated with improved OS (P < 10(-4)). In conclusion, routine ...

    Research Article last updated 07/28/2014 - 8:53am.

  9. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.

    ... that a very high percentage of MDS HSC (92%+/-4%) carry cytogenetic abnormalities. Longitudinal analysis in a patient treated with ... abnormal HSC persist even during complete morphological remission, and that expansion of clonotypic HSC precedes clinical relapse. ...

    Research Article last updated 08/30/2012 - 4:05pm.

  10. Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

    ... cell transplantation is indicated such as: AML in 1st remission - for patients whose AML does not have 'good risk' cytogenetic features (i.e. t 8;21, t15;17, inv 16). Secondary AML in 1st ...

    Clinical Trial last updated 04/29/2016 - 1:59pm.